NCT00464711View on ClinicalTrials.gov

Brain GABA Levels and Treatment Response in Major Depressive Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Major Depressive Disorder
Interventions
DRUG

Escitalopram

Dose determined per clinical discretion. All participants begin on 10mg po qd of escitalopram, and can increase the dose to 30mg po qd over the 12 weeks of the study.

Trial Locations (1)

02114

Depression Clinical and Research Program, Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Mclean Hospital

OTHER

lead

Massachusetts General Hospital

OTHER

NCT00464711 - Brain GABA Levels and Treatment Response in Major Depressive Disorder | Biotech Hunter | Biotech Hunter